- In early August 2026, CVS Health reported second-quarter sales of US$35,117 million and revenue of US$106.10 billion, with net income rising to US$2,979 million and diluted EPS from continuing operations increasing to US$2.31.
- On the same day, CVS Health also raised its 2026 GAAP diluted EPS guidance and expanded its GLP-1 weight management offerings through a lower-cost MinuteClinic program and new Eli Lilly collaboration.
- Next, we’ll examine how CVS Health’s enhanced GLP-1 weight management platform may influence its broader investment narrative and long-term earnings profile.
The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
CVS Health Investment Narrative Recap
To own CVS Health, you need to believe its integrated model across insurance, pharmacy and clinics can still create value despite reimbursement pressure and elevated medical costs. The latest results and raised 2026 EPS guidance support the near term earnings catalyst, while the biggest current risk remains margin pressure in Health Care Benefits if medical cost trends stay high. The GLP 1 expansion is helpful to the story but does not remove that core risk.
The revamped GLP 1 weight management platform, including the Eli Lilly collaboration and lower cost MinuteClinic visits, ties directly to CVS’s push to deepen engagement across its retail and care delivery network. This connects to the earnings catalyst by potentially supporting prescription volumes and clinic utilization across 9,000 locations, although it sits alongside ongoing headwinds from pharmacy reimbursement and group Medicare Advantage repricing cycles.
Yet investors should also weigh how persistent reimbursement pressure across CVS’s retail and PBM businesses could...
Read the full narrative on CVS Health (it's free!)
CVS Health's narrative projects $453.4 billion revenue and $10.7 billion earnings by 2029. This requires 3.8% yearly revenue growth and a $7.8 billion earnings increase from $2.9 billion today.
Uncover how CVS Health's forecasts yield a $114.88 fair value, a 19% upside to its current price.
Exploring Other Perspectives
Four fair value estimates from the Simply Wall St Community span roughly US$104 to US$291 per share, showing how far apart individual views can be. When you compare that spread with current concerns about elevated medical benefit ratios and pressure on CVS’s health insurance margins, it underlines why many investors look at several different viewpoints before deciding how this business might perform.
Explore 4 other fair value estimates on CVS Health - why the stock might be worth just $104.01!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your CVS Health research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
- Our free CVS Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CVS Health's overall financial health at a glance.
Want Some Alternatives?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
- Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com